Advancing the Idiopathic Pulmonary Fibrosis Treatment Landscape: What’s Next in Care

Program Description

Idiopathic pulmonary fibrosis (IPF) is a life-limiting interstitial lung disease characterized by the progressive formation of scar tissue in the lungs, leading to irreversible loss of lung function. With a median survival of just 3 to 5 years after diagnosis, IPF imposes a significant clinical and economic burden on patients and the health care system. Several challenges from delayed diagnosis to underutilization of guideline-recommended antifibrotics and issues with medication adherence and tolerability impact care for patients with IPF. This didactic panel discussion, featuring patient case scenarios and a patient perspective interview, will examine the pathophysiology and clinical burden of IPF, including its impact on quality of life and health care resources. Expert panelists will examine the current treatment landscape and review emerging therapeutic agents. The program will also emphasize the critical role of the specialty pharmacist in optimizing care, focusing on patient counseling, strategies for enhancing adherence, and overcoming common barriers and challenges to ensure patients receive timely and appropriate treatment.

Target Audience: Specialty Pharmacist

Type of Activity: Application
Release date: December 5, 2025
Expiration date: December 5, 2026
Learner level: Foundational, Intermediate
Time to complete activity: 1.5 hour
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Explain the pathophysiology and clinical burden of idiopathic pulmonary fibrosis (IPF)
• Compare currently approved pharmacologic therapies for IPF and their mechanisms of action
• Identify emerging therapeutic agents in the IPF pipeline and their potential impact on clinical care
• Explore the pharmacist’s evolving role in managing patients with IPF, including access, adherence, and patient education

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEU) under the ACPE universal activity number 0290-0000-25-406-H01-P. The activity is available for CE credit through December, 5, 2026.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, view the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Disclosures

Faculty

Kyle Fischer, PharmD, APh; and Mark Schneider, PharmD, have no relevant financial relationships with ineligible companies to disclose.

Justin M. Oldham, MD, PhD, has the following relevant financial relationships with ineligible companies to disclose: Grant/Research Support: Boehringer Ingelheim; Consultant: Boehringer Ingelheim, Bristol Myers Squibb; Mediar Therapeutics, Oorja Bio; Stock: Gatehouse Bio.

Pharmacy Times Continuing Education Planning Staff: Jim Palatine, RPh, MBA; Dipti Desai, PharmD, MBA, CHCP; Victoria Chirdo; Susan Pordon; Brianna Winters; and Chloe Taccetta have no financial relationships with ineligible companies to disclose.

All relevant financial relationships listed for these individuals have been mitigated.

At least one anonymous peer reviewer has been used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with ineligible companies to disclose.

The content of this activity may include information regarding the use of products that may be inconsistent with, or outside the approved labeling for, these products in the United States. Pharmacists should note that the use of these products outside current approved labeling is considered experimental and are advised to consult the prescribing information for these products.

Educational Disclaimer

CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
ceinfo@pharmacytimes.com
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms